Drugs / [177Lu]Lu-PentixaTher
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06356922 | Oct 2024 → Oct 2027 expected | acute leukemia | Nantes University Hospital | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2025-09-25 | Pentixapharm AG | Results Pentixapharm Announces Advancement of PentixaTher to Fourth Dose Level in Acute Myeloid Leukemia Trial pentixapharm.com ↗
Based on favorable safety findings at the third dose level of 7.5 GBq, the investigator-initiated trial received approval from the independent Data Safety Monitoring Board (DSMB) to advance to the fourth of five planned dose levels at 10 GBq, underscoring PentixaTher’s tolerability to date. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2025-09-25 | Pentixapharm AG | Pentixapharm Announces Advancement of PentixaTher to Fourth Dose Level in Acute Myeloid Leukemia Trial pentixapharm.com ↗ |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | [177Lu]Lu-PentixaTher | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06356922 ↗ |
| Action | Inhibit | “CXCR4 inhibition” NCT06356922 ↗ |
| Modality | Other / unclassified | “radioligand therapy (RLT)” NCT06356922 ↗ |
| Route | Other | “Injection of \[177Lu\]Lu-PentixaTher” NCT06356922 ↗ |
| Target | CXCR4 | “CXCR4 inhibition” NCT06356922 ↗ |